Misonix Reports Fourth Quarter and Fiscal Year 2020 Results
Misonix (MSON) reported its fourth quarter and full year 2020 financial results, highlighting a 40.6% revenue increase to $13.7 million in Q4 and a 60.8% rise to $62.5 million for the year. However, net losses grew to $8.5 million for Q4 and $17.4 million for the year, impacted by COVID-19 and increased operating expenses from its Solsys acquisition. The gross profit margin remained strong at 68.8% for Q4 and 70.0% for the year. Misonix is focusing on cash preservation and operational efficiency as it navigates ongoing pandemic challenges.
- Revenue increased 60.8% year-over-year to $62.5 million for fiscal 2020.
- Fourth quarter revenue increased 40.6% year-over-year to $13.7 million.
- Gross profit margin remained high at 70.0% for the full year and 68.8% for Q4.
- Cash reserves grew significantly to $38 million from $7.8 million in the previous year.
- Net loss for Q4 was $8.5 million, up from $2.3 million in the previous year.
- Total operating expenses increased by $7.8 million in Q4 compared to the previous year.
- International revenue declined by 52.6% in Q4, indicating market challenges.
FARMINGDALE, N.Y., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year ended June 30, 2020 as summarized below:
| Three Months Ended | Year Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||
| Revenue | $ | 13,713,231 | $ | 9,754,284 | $ | 62,483,651 | $ | 38,848,491 | |||||
| Gross profit | $ | 9,432,383 | $ | 6,786,138 | $ | 43,709,483 | $ | 27,280,152 | |||||
| Gross profit percentage | 68.8 | % | 69.6 | % | 70.0 | % | 70.2 | % | |||||
| Pretax loss | $ | (8,495,994 | ) | $ | (2,317,250 | ) | $ | (21,916,952 | ) | $ | (7,358,250 | ) | |
| Income tax expense (benefit) | $ | 41,422 | $ | 28,547 | $ | (4,498,578 | ) | $ | 28,547 | ||||
| Net loss | $ | (8,537,416 | ) | $ | (2,345,797 | ) | $ | (17,418,374 | ) | $ | (7,386,797 | ) | |
| EBITDA (1) | $ | (6,415,808 | ) | $ | (1,833,685 | ) | $ | (15,770,303 | ) | $ | (5,694,479 | ) | |
| Adjusted EBITDA (1) | $ | (3,411,151 | ) | $ | 228,112 | $ | (8,820,323 | ) | $ | 132,783 | |||
| June 30, | June 30, | ||||||||||||
| 2020 | 2019 | ||||||||||||
| Cash and cash equivalents | $ | 37,978,809 | $ | 7,842,403 | |||||||||
| Current and Long Term Debt | $ | 43,695,249 | $ | - | |||||||||
| (1) | Definitions and disclosures regarding non-GAAP financial information including reconciliations are included at the end of this press release. |
| On September 27, 2019, Misonix acquired privately held Solsys Medical, LLC (“Solsys”). The actual results presented for the three months ended June 30, 2020 reflect the Company’s legacy Misonix operations as well as revenue and expenses from the acquired Solsys operations. The comparable three-month period ended June 30, 2019 reflects Misonix’s operations only. The actual results presented herein for the twelve months ended June 30, 2020 reflect the Company’s legacy Misonix operations as well as three months and four days of revenue and expenses from the acquired Solsys operations. The comparable twelve-months period ended June 30, 2019 reflects Misonix’s operations only. |
Fourth Quarter and Full Year 2020 Highlights:
- The onset of novel coronavirus disease (“COVID-19”) materially impacted the industry and Misonix’s business in the third and fourth quarters of fiscal 2020 as hospitals were required to postpone elective procedures in order to treat patients effected by the COVID-19 pandemic.
- On July 10, 2020, the Company pre-announced its fourth quarter 2020 revenue results for the three-month period ended June 30, 2020.
- Fourth quarter fiscal 2020 revenue increased
40.6% to$13.7 million , compared to$9.8 million in the fourth quarter of fiscal 2019. On a pro forma basis, assuming Misonix had acquired Solsys for the full fourth quarter of fiscal 2019, total revenue for fiscal fourth quarter 2020 decreased21.6% , including pro forma:
• Domestic revenue decline of13.6%
• International revenue decline of52.6%
- Full fiscal 2020 revenue increased
60.8% to$62.5 million , compared to$38.8 million in full year fiscal 2019. On a pro forma basis, assuming Misonix had acquired Solsys for the full year fiscal 2019, total revenue for full year 2020 increased8.6% , including pro forma:
• Domestic revenue growth of15.3%
• International revenue decline of12.2%
- Gross profit percentage on sales for the fiscal fourth quarter was
68.8% , compared with69.6% in the prior fiscal year comparable quarter, while full year fiscal 2020 gross margin was70.0% , compared to70.2% for the prior full year period.
- Operating expenses increased
$7.8 million during the fiscal fourth quarter of 2020 as compared with the fiscal fourth quarter of 2019 and increased by$28.4 million for the full fiscal year 2020, compared to the prior full year period, resulting from the acquisition of Solsys Medical.
- For the fourth quarter of fiscal 2020, operating expenses declined
$0.9 million , or5.3% from the third quarter of fiscal 2020 as a result of the Company’s cost reduction efforts.
- Net loss for the fiscal fourth quarter of 2020 was
$8.5 million , or a loss of$0.50 per diluted share, compared to a net loss of$2.3 million , or a loss of$0.25 per share, in the prior year comparable period. On a full year basis, net loss was$17.4 million for fiscal 2020, or a loss of$1.19 per diluted share, compared to a net loss of$7.4 million , or a loss of$0.79 per diluted share for fiscal 2019.
- In January 2020, Misonix completed an underwritten public offering yielding net proceeds to the Company of
$32.5 million , through the issuance of 1,868,750 shares of common stock at$18.50 per share.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix stated, “Misonix’s 2020 fiscal fourth quarter and full year financial performance is consistent with the preliminary results we announced in early July and reflects an improvement in domestic procedural volumes during May and June and continued strong sales for our next generation Nexus platform. While the COVID-19 pandemic impacted the global healthcare industry during the second half of our fiscal year, our solid execution combined with contributions from the September 2019 acquisition of Solsys Medical enabled us to achieve year-over-year revenue growth of
“To address the ongoing economic impact of COVID-19 across both our domestic and international markets, we continued to optimize cash preservation in order to maintain the maximum financial flexibility. In this regard, during the three-month period, we meaningfully reduced operating expenses and corporate overhead on a quarterly sequential basis in order to prioritize initiatives focused on revenue generation as we return to normalized operations, including inventory and procurement management, sales force training and development, and new product investments.
“As certain effects of the pandemic on our industry subsided, we saw a pattern of month over month improvement in our sales data from May to June, and an encouraging trend into July. Although the effects of the COVID-19 pandemic on our industry remain uncertain, we are encouraged by early signs of stabilization across our geographic footprint, in particular on the domestic front. At present, we remain focused on driving increased sales productivity and broadening the market penetration of the combined company’s wound and surgical products in operating rooms and hospital outpatient facilities across our markets.
“We believe the safety, efficacy and value that our leading ultrasonic surgical and wound products offer hospitals and outpatient centers, combined with the actions we have taken over the last year to drive efficiencies across our business, position Misonix to leverage the many opportunities to support our goals for growth and enhancement of long-term shareholder value. Looking ahead, we remain confident that our strategic go-to-market initiatives and the active management of our cost structure and balance sheet will enable us to overcome the near-term challenges and address pent-up and new patient demand. I want to thank our employees for their resilience, dedication, and exceptional work as they have gone above and beyond to serve healthcare practitioners and patients under the most challenging of circumstances over the past several months.”
Sales Performance Supplemental Data (unaudited)
| For the three months ended | For the years ended | |||||||||||||||||||||||
| June 30, | Net change | June 30, | Net change | |||||||||||||||||||||
| 2020 | 2019 | $ | % | 2020 | 2019 | $ | % | |||||||||||||||||
| Total | Total | |||||||||||||||||||||||
| Surgical | $ | 5,486,045 | $ | 8,376,277 | $ | (2,890,232 | ) | -34.5 | % | Surgical | $ | 34,457,631 | $ | 33,415,333 | $ | 1,042,298 | 3.1 | % | ||||||
| Wound | 8,227,186 | 1,378,007 | 6,849,179 | 497.0 | % | Wound | 28,026,020 | 5,433,158 | 22,592,862 | 415.8 | % | |||||||||||||
| Total | $ | 13,713,231 | $ | 9,754,284 | $ | 3,958,947 | 40.6 | % | Total | $ | 62,483,651 | $ | 38,848,491 | $ | 23,635,160 | 60.8 | % | |||||||
| Domestic: | Domestic: | |||||||||||||||||||||||
| Surgical | $ | 3,785,450 | $ | 4,816,826 | $ | (1,031,376 | ) | -21.4 | % | Surgical | $ | 20,874,419 | $ | 18,048,956 | $ | 2,825,463 | 15.7 | % | ||||||
| Wound | 8,185,465 | 1,261,226 | 6,924,239 | 549.0 | % | Wound | 27,678,534 | 4,926,752 | 22,751,782 | 461.8 | % | |||||||||||||
| Total | $ | 11,970,915 | $ | 6,078,052 | $ | 5,892,863 | 97.0 | % | Total | $ | 48,552,953 | $ | 22,975,708 | $ | 25,577,245 | 111.3 | % | |||||||
| International: | International: | |||||||||||||||||||||||
| Surgical | $ | 1,700,595 | $ | 3,559,451 | $ | (1,858,856 | ) | -52.2 | % | Surgical | $ | 13,583,212 | $ | 15,366,377 | $ | (1,783,165 | ) | -11.6 | % | |||||
| Wound | 41,721 | 116,781 | (75,060 | ) | -64.3 | % | Wound | 347,486 | 506,406 | (158,920 | ) | -31.4 | % | |||||||||||
| Total | $ | 1,742,316 | $ | 3,676,232 | $ | (1,933,916 | ) | -52.6 | % | Total | $ | 13,930,698 | $ | 15,872,783 | $ | (1,942,085 | ) | -12.2 | % | |||||
Joe Dwyer, Chief Financial Officer, added, “While we are pleased with our ability to generate fiscal fourth quarter and full year 2020 product revenue growth as a result of the Solsys acquisition, our top-line results were not able to fully offset the overall impact of COVID-19 on our business during the three- and twelve-month period ended June 30. As a result, Misonix reported a net loss for the fiscal 2020 fourth quarter and full year of
“Total fiscal fourth quarter operating expenses increased
“At the onset of the pandemic, Misonix took immediate actions to adapt our business to operate in the current environment and to preserve liquidity in order to position the Company best for long-term success as we return to normalized operations. As a result, we ended fiscal 2020 with
“As we enter fiscal 2021, we believe that we are well prepared to meet demand arising from an expected recovery from the effects of COVID-19 and we remain encouraged by the long-term growth trajectory of our products across our surgical and wound divisions. As conditions continue to evolve, the precise depth and duration of COVID-19’s impact on our operations remains uncertain and as a result Misonix is not providing fiscal year 2021 financial guidance at this time.”
Fiscal Fourth Quarter 2020 Conference Call
Misonix will host a conference call and webcast today, Thursday, September 3, 2020, at 4:30 p.m. ET to discuss its financial results and operations and host a question and answer session. The dial in number for the audio conference call is 800-437-2398 (domestic) or 323-289-6576 (international), conference ID 8353775. Participants may also listen to a live webcast of the call at the Company’s website through the “Events and Presentations” section under “Investor Relations” at www.misonix.com. Following its completion, a replay of the webcast will be available for 30 days on the Company’s website, www.misonix.com.
About Misonix, Inc.
Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, the impact of COVID-19, or other pandemics, and the impact of related governmental, individual and business responses. This includes our ability to obtain or forecast accurate surgical procedure volume in the midst of the COVID-19 pandemic; the risk that the COVID-19 pandemic could lead to further material delays and cancellations of, or reduced demand for, surgical procedures; curtailed or delayed capital spending by hospitals and surgical centers; potential closures of our facilities; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus disrupts local economies and causes economies in our key markets to enter prolonged recessions; the ability of our staff to travel to work; our ability to maintain adequate inventories and delivery capabilities; the impact on our customers and supply chain, and the impact on demand in general. These forward-looking statements are also subject to uncertainties and change resulting from delays and risks associated with the performance of contracts; risks associated with international sales and currency fluctuations; uncertainties as a result of research and development; acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy; risks involved in introducing and marketing new products; potential acquisitions; consumer and industry acceptance; litigation and/or court proceedings, including the timing and monetary requirements of such activities; the timing of finding strategic partners and implementing such relationships; regulatory risks including clearance of pending and/or contemplated 510(k) filings; our ability to achieve and maintain profitability in our business lines; access to capital; and other factors described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.
| Contact: | |
| Joe Dwyer | Norberto Aja, Jennifer Neuman |
| Chief Financial Officer | JCIR |
| Misonix, Inc. | 212-835-8500 or mson@jcir.com |
| 631-694-9555 | |
Misonix, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
| For the three months ended | For the years ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Revenue | $ | 13,713,231 | $ | 9,754,284 | $ | 62,483,651 | $ | 38,848,491 | |||||||
| Cost of revenue | 4,280,848 | 2,968,146 | 18,774,168 | 11,568,339 | |||||||||||
| Gross profit | 9,432,383 | 6,786,138 | 43,709,483 | 27,280,152 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling expenses | 11,621,461 | 4,393,479 | 40,232,551 | 18,343,837 | |||||||||||
| General and administrative expenses | 4,133,578 | 3,835,131 | 17,954,567 | 11,878,209 | |||||||||||
| Research and development expenses | 1,214,246 | 897,501 | 4,915,943 | 4,467,969 | |||||||||||
| Total operating expenses | 16,969,285 | 9,126,111 | 63,103,061 | 34,690,015 | |||||||||||
| Loss from operations | (7,536,902 | ) | (2,339,973 | ) | (19,393,578 | ) | (7,409,863 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 28,830 | 30,148 | 90,785 | 89,856 | |||||||||||
| Interest expense | (995,630 | ) | - | (2,620,290 | ) | - | |||||||||
| Other | 7,708 | (7,425 | ) | 6,131 | (38,243 | ) | |||||||||
| Total other income (expense) | (959,092 | ) | 22,723 | (2,523,374 | ) | 51,613 | |||||||||
| Loss from operations before income taxes | (8,495,994 | ) | (2,317,250 | ) | (21,916,952 | ) | (7,358,250 | ) | |||||||
| Income tax benefit (expense) | (41,422 | ) | (28,547 | ) | 4,498,578 | (28,547 | ) | ||||||||
| Net loss | $ | (8,537,416 | ) | $ | (2,345,797 | ) | $ | (17,418,374 | ) | $ | (7,386,797 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic | $ | (0.50 | ) | $ | (0.25 | ) | $ | (1.19 | ) | $ | (0.79 | ) | |||
| Diluted | $ | (0.50 | ) | $ | (0.25 | ) | $ | (1.19 | ) | $ | (0.79 | ) | |||
| Weighted average shares - Basic | 17,177,791 | 9,428,938 | 14,670,663 | 9,333,117 | |||||||||||
| Weighted average shares - Diluted | 17,177,791 | 9,428,938 | 14,670,663 | 9,333,117 | |||||||||||
Misonix, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(unaudited)
| June 30, | June 30, | ||||||
| 2020 | 2019 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 37,978,809 | $ | 7,842,403 | |||
| Accounts receivable, less allowance for doubtful accounts of | 11,064,768 | 5,360,454 | |||||
| Inventories, net | 14,010,684 | 7,353,562 | |||||
| Prepaid expenses and other current assets | 1,668,244 | 835,044 | |||||
| Total current assets | 64,722,505 | 21,391,463 | |||||
| Property, plant and equipment, net of accumulated amortization and depreciation of | 7,304,258 | 4,198,721 | |||||
| Patents, net of accumulated amortization of | 784,318 | 779,100 | |||||
| Goodwill | 108,310,350 | 1,701,094 | |||||
| Contract assets | - | 960,000 | |||||
| Intangible assets | 21,281,136 | - | |||||
| Lease right-of-use assets | 1,098,830 | - | |||||
| Other assets | 322,310 | 920,921 | |||||
| Total assets | $ | 203,823,707 | $ | 29,951,299 | |||
| Liabilities and shareholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 4,273,568 | $ | 5,357,736 | |||
| Accrued expenses and other current liabilities | 7,515,751 | 2,488,514 | |||||
| Current portion of lease liabilities | 414,058 | - | |||||
| Current portion of notes payable | 5,099,744 | - | |||||
| Total current liabilities | 17,303,121 | 7,846,250 | |||||
| Non-current liabilities: | |||||||
| Notes payable | 38,595,505 | - | |||||
| Lease liabilities | 723,553 | - | |||||
| Deferred tax liailities | 33,293 | - | |||||
| Other non-current liabilities | 516,665 | 401,000 | |||||
| Total liabilities | 57,172,137 | 8,247,250 | |||||
| Commitments and contingencies | |||||||
| Shareholders' equity | |||||||
| Common stock, $.0001 and $.01 par value-shares authorized 40,000,000; 17,369,435 and 9,646,728 shares issued and outstanding in each period | 1,737 | 96,468 | |||||
| Additional paid-in capital | 185,961,104 | 43,500,478 | |||||
| Accumulated deficit | (39,311,271 | ) | (21,892,897 | ) | |||
| Total shareholders' equity | 146,651,570 | 21,704,049 | |||||
| Total liabilities and shareholders' equity | $ | 203,823,707 | $ | 29,951,299 | |||
Use of Non-GAAP Financial Measures
The Company has presented the following non-GAAP financial measures in this press release: Pro-forma revenue, EBITDA and Adjusted EBITDA. The Company has presented pro forma revenue in this press release, which is a non-GAAP financial measurement. The Company acquired the operations of Solsys Medical at the end of its first quarter ended September 30, 2019. The Company has presented pro forma revenue to show revenue on a comparable basis as if Solsys had been acquired at the beginning of the comparative periods presented. The Company defines EBITDA as the net income (loss) as reported under GAAP, plus depreciation and amortization expense, interest expense and income tax expense (benefit). The Company defines Adjusted EBITDA as EBITDA plus non-cash stock compensation expense, M&A transaction fees, bad debt expense and engineering costs associated with its development of Nexus, its next generation platform, which we do not expect to recur as the project was completed in the second half of fiscal 2019.
We present these non-GAAP measures because we believe these measures are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as a measure of our operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate the operating performance of companies in our industry. We also believe that these measures are useful to our management and investors as a measure of comparative operating performance from period to period.
Misonix, Inc. and Subsidiaries
Reconciliation of GAAP Results to Non-GAAP Measures
(unaudited)
| Three Months Ended | ||||||||||
| June 30, | Net Increase | |||||||||
| 2020 | 2019 | $ | % | |||||||
| Revenue as reported | $ | 13,713,231 | $ | 9,754,284 | $ | 3,958,947 | 40.6 | % | ||
| Solsys revenue | - | 7,739,052 | ||||||||
| Pro forma revenue | $ | 13,713,231 | $ | 17,493,336 | $ | (3,780,105 | ) | -21.6 | % | |
| Year Ended | ||||||||||
| June 30, | Net Increase | |||||||||
| 2020 | 2019 | $ | % | |||||||
| Revenue as reported | $ | 62,483,651 | $ | 38,848,491 | $ | 23,635,160 | 60.8 | % | ||
| Solsys revenue | 8,381,196 | 26,381,491 | ||||||||
| Pro forma revenue | $ | 70,864,847 | $ | 65,229,982 | $ | 5,634,865 | 8.6 | % | ||
| Three Months Ended | Year Ended | ||||||||||||
| June 30, | June 30, | ||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||
| EBITDA: | |||||||||||||
| Net loss | $ | (8,537,416 | ) | $ | (2,345,797 | ) | $ | (17,418,374 | ) | $ | (7,386,797 | ) | |
| Income tax expense (benefit) | 41,422 | 28,547 | (4,498,578 | ) | 28,547 | ||||||||
| Depreciation and amortization | 1,084,556 | 483,565 | 3,526,359 | 1,663,771 | |||||||||
| Interest expense | 995,630 | - | 2,620,290 | - | |||||||||
| EBITDA | (6,415,808 | ) | (1,833,685 | ) | (15,770,303 | ) | (5,694,479 | ) | |||||
| Non-cash stock compensation | 530,689 | 446,965 | 1,762,628 | 2,336,139 | |||||||||
| M&A transaction fees | - | 1,298,459 | 1,753,384 | 1,396,459 | |||||||||
| Bad debt expense | 2,473,968 | - | 3,433,968 | - | |||||||||
| Nexus next generation engineering | - | 316,373 | - | 2,094,664 | |||||||||
| Adjusted EBITDA | $ | (3,411,151 | ) | $ | 228,112 | $ | (8,820,323 | ) | $ | 132,783 | |||
FAQ
What were Misonix's revenue results for the fiscal year 2020?
What was the net loss for Misonix in the fourth quarter of 2020?
How did COVID-19 impact Misonix's financial results?
What is the cash position of Misonix as of June 30, 2020?
Did Misonix provide financial guidance for fiscal year 2021?
